Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

CAMBRIDGE, Mass., April 22, 2024 -- Editas Medicine, Inc. , a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral...

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Lindac Burkly , ,Broad Institute Cas ,Harvard University Cas ,Editas Medicine Inc ,Broad Institute ,Exchange Commission ,Meeting Of The American Society Gene ,Nasdaq ,Annual Meeting ,American Society ,Cell Therapy ,Executive Vice President ,Chief Scientific Officer ,Editas Medicine ,Based Delivery ,Potential Treatment ,Vivo Gene Therapies ,Abstract Number ,Chemically Modified Ascas ,Thursday Posters ,Gene Disruption ,Metagenomic Discovery ,Novel Recombinase Proteins ,Friday Posters ,Targeted Gene Insertion ,Harvard University ,Private Securities Litigation Reform Act ,Annual Report ,Markets ,